Real-time Estimate
Cboe BZX
18:15:26 21/05/2024 BST
|
5-day change
|
1st Jan Change
|
29.25
USD
|
-1.48%
|
|
-0.95%
|
-8.13%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
96,408
|
161,105
|
172,063
|
192,229
|
140,770
|
131,830
|
-
|
-
|
Enterprise Value (EV)
1 |
85,618
|
145,026
|
152,725
|
169,905
|
112,635
|
105,472
|
98,196
|
91,324
|
P/E ratio
|
43.5
x
|
34.1
x
|
57.8
x
|
35.2
x
|
32.6
x
|
29.9
x
|
21.5
x
|
16.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
18
x
|
15.9
x
|
20.3
x
|
13.2
x
|
8.54
x
|
6.66
x
|
5.58
x
|
4.66
x
|
EV / Revenue
|
16
x
|
14.3
x
|
18
x
|
11.6
x
|
6.84
x
|
5.33
x
|
4.16
x
|
3.23
x
|
EV / EBITDA
|
30.8
x
|
22.1
x
|
46.8
x
|
25.3
x
|
20.1
x
|
16.6
x
|
11.6
x
|
8.34
x
|
EV / FCF
|
68.7
x
|
23.7
x
|
77.3
x
|
47.3
x
|
16.1
x
|
13.8
x
|
16.3
x
|
10.5
x
|
FCF Yield
|
1.46%
|
4.22%
|
1.29%
|
2.12%
|
6.23%
|
7.27%
|
6.13%
|
9.52%
|
Price to Book
|
6.85
x
|
8.5
x
|
7.82
x
|
7.07
x
|
4.5
x
|
3.98
x
|
3.09
x
|
2.58
x
|
Nbr of stocks (in thousands)
|
65,075
|
65,410
|
65,423
|
65,362
|
65,322
|
64,591
|
-
|
-
|
Reference price
2 |
1,482
|
2,463
|
2,630
|
2,941
|
2,155
|
2,041
|
2,041
|
2,041
|
Announcement Date
|
19/02/20
|
23/02/21
|
16/02/22
|
22/02/23
|
14/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5,366
|
10,111
|
8,482
|
14,595
|
16,474
|
19,801
|
23,622
|
28,310
|
EBITDA
1 |
2,777
|
6,572
|
3,266
|
6,719
|
5,616
|
6,360
|
8,436
|
10,948
|
EBIT
1 |
2,638
|
6,313
|
3,018
|
6,357
|
5,321
|
5,369
|
7,930
|
10,573
|
Operating Margin
|
49.16%
|
62.44%
|
35.58%
|
43.56%
|
32.3%
|
27.11%
|
33.57%
|
37.35%
|
Earnings before Tax (EBT)
1 |
2,859
|
5,904
|
3,983
|
7,035
|
5,637
|
5,878
|
8,435
|
10,901
|
Net income
1 |
2,166
|
4,758
|
3,008
|
5,522
|
4,352
|
4,683
|
6,630
|
8,345
|
Net margin
|
40.37%
|
47.06%
|
35.46%
|
37.83%
|
26.42%
|
23.65%
|
28.07%
|
29.48%
|
EPS
2 |
34.03
|
72.21
|
45.54
|
83.65
|
66.02
|
68.15
|
94.92
|
123.5
|
Free Cash Flow
1 |
1,247
|
6,126
|
1,976
|
3,595
|
7,014
|
7,663
|
6,015
|
8,693
|
FCF margin
|
23.24%
|
60.59%
|
23.3%
|
24.63%
|
42.58%
|
38.7%
|
25.46%
|
30.71%
|
FCF Conversion (EBITDA)
|
44.9%
|
93.21%
|
60.5%
|
53.5%
|
124.89%
|
120.49%
|
71.3%
|
79.4%
|
FCF Conversion (Net income)
|
57.57%
|
128.75%
|
65.69%
|
65.1%
|
161.17%
|
163.64%
|
90.72%
|
104.18%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/02/20
|
23/02/21
|
16/02/22
|
22/02/23
|
14/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
6,343
|
3,553
|
2,310
|
2,619
|
2,119
|
3,162
|
5,281
|
4,087
|
5,227
|
2,854
|
4,198
|
7,052
|
4,744
|
4,678
|
4,143
|
4,992
|
9,039
|
5,287
|
5,585
|
5,224
|
EBITDA
1 |
4,583
|
1,345
|
905
|
1,016
|
529
|
1,263
|
1,792
|
1,953
|
2,974
|
458
|
1,520
|
1,978
|
1,739
|
1,899
|
823
|
1,512
|
2,412
|
1,716
|
2,085
|
2,841
|
EBIT
1 |
4,568
|
1,319
|
890
|
809
|
514
|
1,247
|
1,761
|
1,931
|
2,665
|
437
|
1,497
|
1,934
|
1,717
|
1,670
|
801
|
391.8
|
2,229
|
1,633
|
1,832
|
1,541
|
Operating Margin
|
72.02%
|
37.12%
|
38.53%
|
30.89%
|
24.26%
|
39.44%
|
33.35%
|
47.25%
|
50.99%
|
15.31%
|
35.66%
|
27.42%
|
36.19%
|
35.7%
|
19.33%
|
7.85%
|
24.66%
|
30.89%
|
32.81%
|
29.5%
|
Earnings before Tax (EBT)
1 |
4,682
|
1,846
|
1,171
|
966
|
612
|
2,489
|
3,101
|
3,272
|
662
|
286
|
1,723
|
2,009
|
2,702
|
926
|
1,716
|
184.1
|
3,374
|
1,693
|
1,715
|
1,626
|
Net income
1 |
3,647
|
1,402
|
890
|
716
|
465
|
1,891
|
2,356
|
2,582
|
584
|
226
|
1,357
|
1,583
|
2,129
|
640
|
1,325
|
455.1
|
2,598
|
1,360
|
1,345
|
1,274
|
Net margin
|
57.5%
|
39.46%
|
38.53%
|
27.34%
|
21.94%
|
59.8%
|
44.61%
|
63.18%
|
11.17%
|
7.92%
|
32.32%
|
22.45%
|
44.88%
|
13.68%
|
31.98%
|
9.12%
|
28.74%
|
25.73%
|
24.07%
|
24.4%
|
EPS
2 |
55.52
|
21.25
|
13.47
|
10.82
|
7.050
|
28.66
|
35.71
|
39.17
|
8.820
|
3.430
|
20.61
|
24.03
|
32.32
|
9.670
|
20.18
|
-2.267
|
39.51
|
19.26
|
18.88
|
14.82
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/08/20
|
11/08/21
|
10/11/21
|
16/02/22
|
11/05/22
|
10/08/22
|
10/08/22
|
09/11/22
|
22/02/23
|
10/05/23
|
03/08/23
|
03/08/23
|
07/11/23
|
14/02/24
|
02/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
10,790
|
16,079
|
19,338
|
22,324
|
28,135
|
26,359
|
33,634
|
40,507
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1,247
|
6,126
|
1,976
|
3,595
|
7,014
|
7,663
|
6,015
|
8,693
|
ROE (net income / shareholders' equity)
|
19.6%
|
28.7%
|
14.6%
|
22.2%
|
14.8%
|
15.5%
|
16.5%
|
17.8%
|
ROA (Net income/ Total Assets)
|
18.4%
|
26.2%
|
13.1%
|
20.1%
|
13.3%
|
13.7%
|
14%
|
16.2%
|
Assets
1 |
11,803
|
18,143
|
22,885
|
27,453
|
32,704
|
34,097
|
47,522
|
51,566
|
Book Value Per Share
2 |
216.0
|
290.0
|
336.0
|
416.0
|
479.0
|
513.0
|
660.0
|
793.0
|
Cash Flow per Share
2 |
21.50
|
97.60
|
33.70
|
59.30
|
112.0
|
95.20
|
126.0
|
163.0
|
Capex
1 |
79
|
307
|
252
|
317
|
366
|
501
|
515
|
647
|
Capex / Sales
|
1.47%
|
3.04%
|
2.97%
|
2.17%
|
2.22%
|
2.53%
|
2.18%
|
2.28%
|
Announcement Date
|
19/02/20
|
23/02/21
|
16/02/22
|
22/02/23
|
14/02/24
|
-
|
-
|
-
|
Last Close Price
2,041
DKK Average target price
2,470
DKK Spread / Average Target +21.01% Consensus |
1st Jan change
|
Capi.
|
---|
| +7.88% | 115B | | +12.88% | 107B | | -13.56% | 22.31B | | -3.99% | 21.6B | | -6.59% | 18.23B | | -39.93% | 17.62B | | +6.93% | 14.26B | | +33.06% | 12.37B | | -28.05% | 8.28B |
Bio Therapeutic Drugs
|